Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

ABSTRACT: Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

PROVIDER: PRJEB28341 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR2808070_1.fastq.gz	Fastqsanger.gz
	ERR2808070_2.fastq.gz	Fastqsanger.gz
	ERR2808080_1.fastq.gz	Fastqsanger.gz
	ERR2808080_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 373

Similar Datasets

Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Project description:Ceftriaxone has a higher biliary elimination than cefotaxime (40% versus 10%), which may result in a more pronounced impact on the intestinal microbiota. We performed a monocenter, randomized open-label clinical trial in 22 healthy volunteers treated by intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for 3 days. We collected fecal samples for phenotypic analyses, 16S rRNA gene profiling, and measurement of the antibiotic concentration and compared the groups for the evolution of microbial counts and indices of bacterial diversity over time. Plasma samples were drawn at day 3 for pharmacokinetic analysis. The emergence of 3rd-generation-cephalosporin-resistant Gram-negative enteric bacilli (Enterobacterales), Enterococcus spp., or noncommensal microorganisms was not significantly different between the groups. Both antibiotics reduced the counts of total Gram-negative enteric bacilli and decreased the bacterial diversity, but the differences between the groups were not significant. All but one volunteer from each group exhibited undetectable levels of antibiotic in feces. Plasma pharmacokinetic endpoints were not correlated to alteration of the bacterial diversity of the gut. Both antibiotics markedly impacted the intestinal microbiota, but no significant differences were detected when standard clinical doses were administered for 3 days. This might be related to the similar daily amounts of antibiotics excreted through the bile using a clinical regimen. (This study has been registered at ClinicalTrials.gov under identifier NCT02659033.).

| S-EPMC6535507 | biostudies-literature

Effect of ceftriaxone treatment on gene expression of MYCN-amplified RB170

Project description:To study the gene expression response of RB170 to ceftriaxone treatment. We performed gene expression profiling analysis using data obtained from RNA-seq of 3 different ceftriaxone concentration cells at two days of treatment.

2023-11-22 | GSE240841 | GEO

Transcriptional profiling of extraintestinal Escherichia coli exposed to cranberry pomace extracts alone or in combination with ceftriaxone

Project description:To investigate the effects of ceftriaxone and cranberry pomace extract on transcriptome of extraintestinal E. coli (ExPEC)

2023-06-01 | GSE205240 | GEO

Ceftriaxone resistant H58 Salmonella Typhi

Project description:Ceftriaxone resistant H58 Salmonella Typhi

| PRJEB21155 | ENA

Ceftriaxone resistant Neisseria gonorrhoeae

Project description:A ceftriaxone resistant Neisseria gonorrhoeae infection acquired in Denmark in 2017

| PRJEB22246 | ENA

Ceftriaxone resistant S. Typhi

Project description:Ceftriaxone resistant Salmonella Typhi carries an IncI1-ST31 plasmid encoding CTX-M-15

| PRJEB21992 | ENA

Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial.

Project description:Azithromycin or doxycycline is recommended for nongonococcal urethritis (NGU); recent evidence suggests their efficacy has declined. We compared azithromycin and doxycycline in men with NGU, hypothesizing that azithromycin was more effective than doxycycline.From January 2007 to July 2011, English-speaking males ?16 years, attending a sexually transmitted diseases clinic in Seattle, Washington, with NGU (visible urethral discharge or ?5 polymorphonuclear leukocytes per high-power field [PMNs/HPF]) were eligible for this double-blind, parallel-group superiority trial. Participants received active azithromycin (1 g) + placebo doxycycline or active doxycycline (100 mg twice daily for 7 days) + placebo azithromycin. Urine was tested for Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Ureaplasma urealyticum biovar 2 (UU-2), and Trichomonas vaginalis (TV) using nucleic acid amplification tests. Clinical cure (<5 PMNs/HPF with or without urethral symptoms and absence of discharge) and microbiologic cure (negative tests for CT, MG, and/or UU-2) were determined after 3 weeks.Of 606 men, 304 were randomized to azithromycin and 302 to doxycycline; CT, MG, TV, and UU-2 were detected in 24%, 13%, 2%, and 23%, respectively. In modified intent-to-treat analyses, 172 of 216 (80%; 95% confidence interval [CI], 74%-85%) receiving azithromycin and 157 of 206 (76%; 95% CI, 70%-82%) receiving doxycycline experienced clinical cure (P = .40). In pathogen-specific analyses, clinical cure did not differ by arm, nor did microbiologic cure differ for CT (86% vs 90%, P = .56), MG (40% vs 30%, P = .41), or UU-2 (75% vs 70%, P = .50). No unexpected adverse events occurred.Clinical and microbiologic cure rates for NGU were somewhat low and there was no significant difference between azithromycin and doxycycline. Mycoplasma genitalium treatment failure was extremely common. Clinical Trials Registration.NCT00358462.

| S-EPMC3588116 | biostudies-literature

NIH 3T3 fibroblast cells with Ceftriaxone Treatment

Project description:NIH 3T3 cells were plated at 1.5million cells per 10cM dish into 12 10cm dishes. 24hrs post plating media was changed on all plates. At the time of media change, 4 dishes were treated with a final concentration of 50uM ceftriaxone (24hrs ceftriaxone n=4). 23 hrs post media change, 4 separate dishes were treated with 50uM ceftriaxone for 1hr (1hr ceftriaxone n=4). 4 dishes were untreated (0hr, basal, n=4). 24 hrs post media change, media was quickly removed from all 12 plates, each plate was rapidly washed with MilliQ H2O and rapidly frozen with liquid nitrogen poured directly into the dishes. All plates were transferred to dry ice and stored at -80 until shipped.

2017-06-19 | ST000702 | MetabolomicsWorkbench

Muscle H3K27ac landscape remodeling with glucocorticoid steroid regimens

Project description:Muscle H3K27ac landscape remodeling with glucocorticoid steroid regimens

| PRJNA574123 | ENA

Comparing gene expression in stem/progenitor cells from patients with CML in chronic, accelerated and blastic phase with normal volunteers

Project description:A comparison of global gene expression between rigorously defined stem and progenitor cells from patients with chronic myeloid leukaemia (CML) in chronic (CP), accelerated (AP) and blastic (BC) phase and similar populations isolated from normal volunteers.

2013-09-06 | GSE47927 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data